Mousavinezhad Maryam, Majdzadeh Reza, Akbari Sari Ali, Delavari Alireza, Mohtasham Farideh
BPH, MSc, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
DVM, MSc, PhD, Professor, School of Public Health and Knowledge Utilization Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Med J Islam Repub Iran. 2016 May 9;30:366. eCollection 2016.
After lung and prostate cancers, colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in women after breast cancer worldwide. Every year, more than one million people are diagnosed with colorectal cancer worldwide and half of these patients die from this disease, making it the fourth leading cause of death in the world. This systematic review aimed to assess the effectiveness of the two colorectal diagnostic tests of FOBT (fecal occult blood test) and FIT (fecal immunochemical test)) in terms of technical performance.
To retrieve the relevant evidence, appropriate medical databases such as Cochrane library, NHSEED, Scopus and Google scholar were searched from February 2013 to July 2014, using free-texts and Mesh. In this study, inclusion/exclusion criteria of the papers, randomized controlled trials, economic evaluations, systematic reviews, meta-analyses and meta-syntheses of the effectiveness of FIT versus FOBT tests in moderate-risk populations (age: 50 to 70 years), which had reported the least of such outcomes as sensitivity, specificity and clinical outcomes were reviewed. The analyses of the effectiveness outcomes were performed in the form of meta-analysis.
Five papers were eligible to be included in the final phase of the study for synthesis. FIT showed a better performance in participation and positivity rate. Moreover, in terms of false positive and negative rate, FIT showed fewer rates compared to FOBT (RR:-4.06; 95% CI (-7.89-0.24), and NN-scope (Number need to scope) (2.2% vs. 1.6%), and NN-screen (Number need to screen) (84% vs. 31-49% in different cut off levels) showed significant differences in FOBT vs. FIT, respectively.
In the five included studies (3, 11-14), the acceptability of FIT was more than FOBT. However, in our meta-analysis, no difference was found between the two tests. FIT was significant in positivity rate and had a better performance in participation rate, and a fewer false negative numbers compared to FOBT.
在肺癌和前列腺癌之后,结直肠癌(CRC)是全球男性中第三常见的癌症,在女性中是仅次于乳腺癌的第二常见癌症。每年,全球有超过100万人被诊断为结直肠癌,其中一半患者死于该病,使其成为全球第四大死因。本系统评价旨在评估粪便潜血试验(FOBT)和粪便免疫化学试验(FIT)这两种结直肠癌诊断试验在技术性能方面的有效性。
为检索相关证据,于2013年2月至2014年7月使用自由文本和医学主题词(Mesh)检索了Cochrane图书馆、NHSEED、Scopus和谷歌学术等适当的医学数据库。在本研究中,对中度风险人群(年龄:50至70岁)中FIT与FOBT检测有效性的论文、随机对照试验、经济评估、系统评价、荟萃分析和荟萃综合的纳入/排除标准进行了审查,这些研究至少报告了敏感性、特异性和临床结果等结果。有效性结果分析以荟萃分析的形式进行。
五篇论文符合纳入研究的最后阶段进行综合分析的条件。FIT在参与率和阳性率方面表现更好。此外,在假阳性和假阴性率方面,FIT与FOBT相比发生率更低(相对风险(RR):-4.06;95%置信区间(CI)(-7.89 - 0.24)),且在不同截断水平下,每筛查出一例阳性所需的人数(NN-scope)(2.2%对1.6%)和每筛查出一例病例所需的人数(NN-screen)(84%对31 - 49%)在FOBT与FIT之间分别显示出显著差异。
在纳入的五项研究(3、11 - 14)中,FIT的可接受性高于FOBT。然而,在我们的荟萃分析中,未发现两种检测之间存在差异。FIT在阳性率方面显著,参与率表现更好,与FOBT相比假阴性数量更少。